Here, the authors show that cancer cells with KRAS mutations promote MPE by recruiting myeloid cells via CCL2 signalling and that pharmaceutical targeting of KRAS results in reduced MPE incidence and volume in mouse models. Here, CCL2 is linked to cancer.